German life sciences and pharma company Merck KGaA (MRK: DE) has entered into a research agreement with South Korea’s International Vaccine Institute (IVI) to develop better purification processes.
The new collaboration is promised to improve manufacturing to deliver greater yield, allowing higher recovery and providing greater purity vaccines.
IVI is a non-profit international organization committed to the discovery, development and delivery of safe, effective and affordable vaccines for global public health.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze